Mary Anne Dellva Selected Research

Norepinephrine (Noradrenaline)

5/2016	Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.
1/2015	Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorder.
1/2014	A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.
6/2011	A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder.
4/2010	A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mary Anne Dellva Research Topics

Disease

6	Major Depressive Disorder (Major Depressive Disorders) 05/2016 - 04/2010
5	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2022 - 10/2020
3	Type 2 Diabetes Mellitus (MODY) 01/2022 - 12/2020
2	Injection Site Reaction 02/2021 - 10/2020
2	Nausea 01/2014 - 04/2010
2	Psychotic Disorders (Schizoaffective Disorder) 04/2010 - 08/2007
2	Schizophrenia (Dementia Praecox) 04/2010 - 08/2007
1	Erectile Dysfunction 01/2014
1	Pain (Aches) 01/2014
1	Fatigue 01/2014
1	Hyperhidrosis 01/2014
1	Headache (Headaches) 04/2010
1	Bipolar Disorder (Manic Depressive Psychosis) 04/2010
1	Constipation 04/2010
1	Dementia (Dementias) 04/2010
1	Sleep Initiation and Maintenance Disorders (Insomnia) 04/2010
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 03/2007

Drug/Important Bio-Agent (IBA)

8	Insulin Lispro (Humalog)FDA Link 01/2022 - 10/2020
6	alpha- ((5- fluoro- 2- methoxyphenyl)methyl)- alpha- (tetrahydro- 2H- pyran- 4- yl)- 2- morpholinemethanolIBA 05/2016 - 04/2010
5	Norepinephrine (Noradrenaline)FDA LinkGeneric 05/2016 - 04/2010
4	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 05/2016 - 01/2014
3	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 10/2020
2	Antidepressive Agents (Antidepressants)IBA 06/2015 - 01/2015
1	Olanzapine (Zyprexa)FDA Link 04/2010
1	Antipsychotic Agents (Antipsychotics)IBA 08/2007
1	Atomoxetine Hydrochloride (Strattera)FDA LinkGeneric 03/2007

Therapy/Procedure

2	Therapeutics 05/2016 - 06/2015
1	Duration of Therapy 08/2007